Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Ravkilde

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 18, 2009
Randomized comparison of deliverability and in-hospital complications in implantation of BxSonic(R), Express(R), and Flexmaster(R) coronary stentsLeif Thuesen, Anders Galløe, Per Thayssen, et al.
Lancet (London, England)|September 9, 2015
Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trialThomas Engstrøm, Henning Kelbæk, Steffen Helqvist, et al.
Circulation. Cardiovascular Interventions|April 14, 2017
Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization)Jacob Lønborg, Thomas Engstrøm, Henning Kelbæk, et al.
The American Journal of Cardiology|February 7, 2018
Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy)Golnaz Sadjadieh, Thomas Engstrøm, Steffen Helqvist, et al.
Journal of the American College of Cardiology|August 7, 2010
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) TrialAnne Kaltoft, Henning Kelbaek, Leif Thuesen, et al.
JACC. Cardiovascular Interventions|May 21, 2013
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction)Lene Holmvang, Henning Kelbæk, Anne Kaltoft, et al.
Journal of the American College of Cardiology|March 1, 2008
Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trialHenning Kelbaek, Christian J Terkelsen, Steffen Helqvist, et al.
Lancet (London, England)|February 5, 2013
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trialEvald Høj Christiansen, Lisette Okkels Jensen, Per Thayssen, et al.
The American Journal of Cardiology|August 26, 2011
Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy)Michael Maeng, Lisette O Jensen, Hans-Henrik Tilsted, et al.
Circulation|August 30, 2008
Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trialHenning Kelbaek, Leif Thuesen, Steffen Helqvist, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|September 18, 2009
Randomized comparison of deliverability and in-hospital complications in implantation of BxSonic(R), Express(R), and Flexmaster(R) coronary stentsLeif Thuesen, Anders Galløe, Per Thayssen, et al.
Lancet (London, England)|September 9, 2015
Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trialThomas Engstrøm, Henning Kelbæk, Steffen Helqvist, et al.
Circulation. Cardiovascular Interventions|April 14, 2017
Fractional Flow Reserve-Guided Complete Revascularization Improves the Prognosis in Patients With ST-Segment-Elevation Myocardial Infarction and Severe Nonculprit Disease: A DANAMI 3-PRIMULTI Substudy (Primary PCI in Patients With ST-Elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization)Jacob Lønborg, Thomas Engstrøm, Henning Kelbæk, et al.
The American Journal of Cardiology|February 7, 2018
Relation of Bleeding Events to Mortality in Patients With ST-Segment Elevation Myocardial Infarction Treated by Percutaneous Coronary Intervention (a DANAMI-3 Substudy)Golnaz Sadjadieh, Thomas Engstrøm, Steffen Helqvist, et al.
Journal of the American College of Cardiology|August 7, 2010
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) TrialAnne Kaltoft, Henning Kelbaek, Leif Thuesen, et al.
JACC. Cardiovascular Interventions|May 21, 2013
Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction)Lene Holmvang, Henning Kelbæk, Anne Kaltoft, et al.
Journal of the American College of Cardiology|March 1, 2008
Randomized comparison of distal protection versus conventional treatment in primary percutaneous coronary intervention: the drug elution and distal protection in ST-elevation myocardial infarction (DEDICATION) trialHenning Kelbaek, Christian J Terkelsen, Steffen Helqvist, et al.
Lancet (London, England)|February 5, 2013
Biolimus-eluting biodegradable polymer-coated stent versus durable polymer-coated sirolimus-eluting stent in unselected patients receiving percutaneous coronary intervention (SORT OUT V): a randomised non-inferiority trialEvald Høj Christiansen, Lisette Okkels Jensen, Per Thayssen, et al.
The American Journal of Cardiology|August 26, 2011
Outcome of sirolimus-eluting versus zotarolimus-eluting coronary stent implantation in patients with and without diabetes mellitus (a SORT OUT III Substudy)Michael Maeng, Lisette O Jensen, Hans-Henrik Tilsted, et al.
Circulation|August 30, 2008
Drug-eluting versus bare metal stents in patients with st-segment-elevation myocardial infarction: eight-month follow-up in the Drug Elution and Distal Protection in Acute Myocardial Infarction (DEDICATION) trialHenning Kelbaek, Leif Thuesen, Steffen Helqvist, et al.
Pageof 9